MESO

Mesoblast (MESO)

About Mesoblast (MESO)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Details

Daily high

$14.42

Daily low

$14.07

Price at open

$14.08

52 Week High

$21.50

52 Week Low

$9.61

Market cap

1.8B

Dividend yield

0.00%

Volume

239,668

Avg. volume

347,161

P/E ratio

-19.01

Mesoblast News